TRIALS on going
To date, there are no results from large, well-designed multicentre
clinical trials establishing the efficacy of PT in patients with
COVID-19.During this period numerous ttrials worldwide are being
conducted to assess the efficacy and safety of PT in COVID-19 patients.
Six clinical trials are underway in Italy.the first. Table 1 shows the
studies in progress in Italy. In most of these studies it will use the
dose based on experience published in the literature, 250-300 mL of
convalescent plasma will be used to treat each of the patients recruited
a maximum of 3 times in 5 days. The main outcomes that will be evaluated
are the trend in the concentration of inflammatory markers, the viral
load, the remission of clinical symptoms, the number of healings. The
various trials conducted in Italy and around the world will provide
important EBM that will provide valuable information on the real
effectiveness of PT in COVID-19 patients, the right dose to use, the
time to take plasma from cured patients, the safety of therapy.
(tab.1 )